Abbott Reviews Strong Ongoing Third One fourth Results Abbott’s worldwide sales increased 13 ed pills .2 % to $9.8 billion, including a good 5.3 % effect of forex. Proprietary Pharmaceuticals sales increased 13.5 % in the quarter. Durable Growth Business sales increased 15.3 %, including double-digit growth in Nutritionals, Established Pharmaceuticals, Core Laboratory Diabetes and Diagnostics Treatment. Innovation-Driven Device Business sales elevated 6.0 %, including double-digit growth in Molecular Diagnostics. Diluted revenue per talk about, excluding specified items, were $1.18, at the high end of Abbott’s previous guidance range, reflecting 12.4 % growth.